Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Halaven and Bavencio in Metastatic Urothelial Cell Cancer
NCT03502681Phase 1Terminated
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eribulin in urothelial carcinoma (TCC). Started Jun 2018; status: terminated.
02
Drugs
eribulin
03
Conditions
urothelial carcinoma (TCC)
Beyond the preview
Go deeper on NCT03502681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502681.